Connection

MICHAEL TAYLOR to Xenograft Model Antitumor Assays

This is a "connection" page, showing publications MICHAEL TAYLOR has written about Xenograft Model Antitumor Assays.
  1. Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nat Med. 2020 05; 26(5):720-731.
    View in: PubMed
    Score: 0.127
  2. Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy. Cancer Res. 2025 Oct 01; 85(19):3737-3751.
    View in: PubMed
    Score: 0.046
  3. Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma. Cancer Res. 2019 05 01; 79(9):2111-2123.
    View in: PubMed
    Score: 0.029
  4. Divergent clonal selection dominates medulloblastoma at recurrence. Nature. 2016 Jan 21; 529(7586):351-7.
    View in: PubMed
    Score: 0.024
  5. MLL5 Orchestrates a Cancer Self-Renewal State by Repressing the Histone Variant H3.3 and Globally Reorganizing Chromatin. Cancer Cell. 2015 Dec 14; 28(6):715-729.
    View in: PubMed
    Score: 0.023
  6. Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR. Nat Genet. 2014 Jan; 46(1):39-44.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.